Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Vastra Gotaland Region
Endeavor Biomedicines, Inc.
University Hospital, Lille
PrECOG, LLC.
Lumicell, Inc.
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
Ipsen
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
PharmaMar
Azienda USL Reggio Emilia - IRCCS
Columbia University
University Hospital Southampton NHS Foundation Trust
Memorial Sloan Kettering Cancer Center
University of Southampton
Gruppo Oncologico Italiano di Ricerca Clinica
Ipsen
Radboud University Medical Center
Canadian Cancer Trials Group
Symphogen A/S
Ain Shams University
University of Chicago
Bristol-Myers Squibb
Amphera BV
University of Chicago
Massachusetts General Hospital
Polaris Group
University of Florida
University of Hull
Candel Therapeutics, Inc.
PrECOG, LLC.
Eastern Cooperative Oncology Group
Intergroupe Francophone de Cancerologie Thoracique
Memorial Sloan Kettering Cancer Center
Xencor, Inc.
M.D. Anderson Cancer Center
Baylor College of Medicine
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Calithera Biosciences, Inc
Augusta University
Radboud University Medical Center
Stony Brook University
AbbVie
AbbVie
Eli Lilly and Company